Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment
Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas